Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conversion Clear all
Withdrawn Phase 1Phase 2 Interventional

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

NCT00777400
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
Efalizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

NCT00418600
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provitamin A Absorption and Conversion With Avocados

NCT01432210
View directory record Official record
Conditions
Healthy
Interventions
Post-prandial Feeding Study
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting No phase listed Observational

Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND

NCT06362161
View directory record Official record
Conditions
Functional Neurological Disorder, Convulsion, Non-Epileptic, Functional Seizure
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 89 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

NCT05712421
View directory record Official record
Conditions
Hypothyroidism
Interventions
North Star, Levothyroxine
Drug
Lead sponsor
Neuvosyn Laboratories, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Canoga Park, California • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

NCT00048035
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

NCT00496483
View directory record Official record
Conditions
Renal Failure
Interventions
LCP Tacro (tacrolimus), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)

NCT03824197
View directory record Official record
Conditions
Alzheimer Disease, Cerebral Amyloid Angiopathy
Interventions
EVOO, OO
Other
Lead sponsor
Auburn University
Other
Eligibility
55 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Results available

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

NCT00160199
View directory record Official record
Conditions
Secondary Amenorrhea
Interventions
PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
42
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incidence of COVID-19 Test Conversion in Post-surgical Patients

NCT04392323
View directory record Official record
Conditions
Sars-CoV2
Interventions
COVID-19 PCR and Serology
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 2:43 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Conversion of Labor Analgesia for Intrapartum Cesarean Delivery: DPE v CSE v Epidural

NCT05514431
View directory record Official record
Conditions
Anesthesia, Analgesia
Interventions
Epidural, Dural Puncture Epidural (DPE) technique, Combined Spinal-Epidural (CSE) technique
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

ASSURE WCD Clinical Evaluation - Conversion Efficacy Study

NCT04132466
View directory record Official record
Conditions
Death, Sudden, Cardiac
Interventions
Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system
Device
Lead sponsor
Kestra Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Anchorage, Alaska • Ann Arbor, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

NCT01935128
View directory record Official record
Conditions
Renal Transplant
Interventions
Arm 1 Everolimus/Reduced dose tacrolimus
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275
View directory record Official record
Conditions
Parkinson Disease
Interventions
Requip PR, Mirapex
Drug
Lead sponsor
Rajesh Pahwa, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

NCT06395662
View directory record Official record
Conditions
Radiologically Isolated Syndrome, Multiple Sclerosis
Interventions
Observational
Other
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Other
Eligibility
Not listed
Enrollment
320 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

NCT02014103
View directory record Official record
Conditions
Complication of Transplant
Interventions
Prograf, Tacrolimus, Sandoz, Tacrolimus, Reddy Laboratory, Tacrolimus, Mylan, Tacrolimus, Accord, Tacrolimus, Pancea Biotech Limited
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

NCT00086346
View directory record Official record
Conditions
Liver Transplantation
Interventions
Sirolimus (Rapamune), Cyclosporine or Tacrolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
10
States / cities
San Francisco, California • Tampa, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

NCT00633009
View directory record Official record
Conditions
Cutaneous Leishmaniasis
Interventions
Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo)
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 23, 2026, 2:43 AM EDT